Results 91 to 100 of about 64,258 (204)

The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas

Tumor Biology, 2017
Pancreatic ductal adenocarcinoma is a highly malignant tumor with poor prognosis, and the biomarkers for the early diagnosis, targeting therapy, and prognosis are still not clinically available.
Xin Luo, Zhulin Yang, Xiao Liu, Ziru Liu, Xiongying Miao, Daiqiang Li, Qiong Zou, Yuan Yuan   +7 more
doaj   +1 more source

Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.

PLoS ONE, 2021
Background/objectivesPancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only marginally prolongs patient survival.
Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-Gispert, Leo Bühler, Bernhard Egger   +5 more
doaj   +1 more source

Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR) : an international multicenter analysis [PDF]

, 2019
Background: Distal pancreatectomy with celiac axis resection (DP-CAR) is a treatment option for selected patients with pancreatic cancer involving the celiac axis.
Adham, Mustapha, Bassi, Claudio, Berrevoet, Frederik, Besselink, Marc G, Boggi, Ugo, Busch, Olivier R, Cesaretti, Manuela, Dalla Valle, Raffaele, Darnis, Benjamin, Del Chiaro, Marco, Diener, Markus K, Dumitrascu, Traian, Friess, Helmut, Fusai, Giuseppe K, Gerritsen, Sarah L, Gruetzmann, Robert, Hackert, Thilo H, Hirono, Seiko, Hogg, Melissa E, Ivanecz, Arpad, Javed, Ammar A, Karayiannakis, Anastasios, Kawai, Manabu, Kleeff, Jorg, Klompmaker, Sjors, Labori, Knut J, Lesurtel, Mickael, Lombardo, Carlo, Lopez-Ben, Santiago, Mabrut, Jean-Yves, Miyazawa, Motoki, Moser, A James, Niesen, Willem, Okada, Ken-ichi, Pardo, Fernando, Perinel, Julie, Peters, Niek A, Popescu, Irinel, Prasad, Raj, Roeyen, Geert, Salvia, Roberto, Sauvanet, Alain, Sturesson, Christian, Teresa Albiol, M, Van Gulik, Thomas M, Van Hilst, Jony, Weiss, Matthew J, Wolfgang, Christopher L, Yamaue, Hiroki, Zeh, Herbert J, Zureikat, Amer H   +50 more
core   +2 more sources

TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors. [PDF]

, 2015
The genomic regulatory programmes that underlie human organogenesis are poorly understood. Pancreas development, in particular, has pivotal implications for pancreatic regeneration, cancer and diabetes.
A Kapoor, A Krapp, A Rada-Iglesias, A Sawada, A-C Binot, AF Hezel, AJ Saldanha, B Zhao, B Zhao, C Cortijo, C Haumaitre, C Trapnell, CHH Cho, CY McLean, DA Stoffers, DW Huang, E Kroon, E Rodríguez-Seguel, EF Chiang, F Argenton, F Esni, F Supek, FC Lynn, FC Pan, H Fang, H Fang, H Lango Allen, I Morán, I Rooman, J Bessa, J van Arensbergen, JM Oliver-Krasinski, K Kawakami, K Piper, K Piper, K Skouloudaki, KJ Gaulton, KM Petzold, KS Zaret, L Elghazi, L Pasquali, M Borowiak, M Carrasco, M Gannon, MA Maestro, MC Whitlock, MF Offield, MJL de Hoon, MN Weedon, MP Creyghton, N Bardeesy, N Gao, NM George, P Jacquemin, PA Seymour, R O’Rahilly, R Xie, RE Jennings, RF Luco, S Gupta, S Heinz, S Xuan, T Derrien, T Jowett, W Zhang, WA Whyte, Y Fujitani, Y Liu-Chittenden   +67 more
core   +2 more sources

LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis

Molecular Cancer, 2018
Background Defective autophagy is thought to contribute to the pathogenesis of many diseases, including cancer. Human plasmacytoma variant translocation 1 (PVT1) is an oncogenic long non-coding RNA that has been identified as a prognostic biomarker in ...
Fengting Huang, Wenying Chen, Juanfei Peng, Yuanhua Li, Yanyan Zhuang, Zhe Zhu, Chunkui Shao, Wanling Yang, Herui Yao, Shineng Zhang   +9 more
doaj   +1 more source

Metabolic Dependencies in Pancreatic Cancer. [PDF]

, 2018
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only marginal therapeutic efficacy. FDA approved drugs currently used against
Brody, Jonathan R., Vaziri-Gohar, Ali, Winter, Jordan M., Zarei, Mahsa   +3 more
core   +1 more source

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. [PDF]

, 2015
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The aggressiveness and therapeutic recalcitrance of this malignancy has been attributed to multiple factors including the influence of an active desmoplastic stroma.
Balaji, Uthra, Freinkman, Elizaveta, Knudsen, Erik S., McCue, Peter, Witkiewicz, Agnieszka K.   +4 more
core   +2 more sources

Diagnosis and staging of pancreatic ductal adenocarcinoma

Clinical and Translational Oncology, 2017
The management of pancreatic ductal adenocarcinoma (PDAC) is a major public health concern worldwide. Currently, most PDAC patients are diagnosed in advanced stages. The signs and symptoms of the disease, except for jaundice, are non-specific. Thus, the current challenge is to identify earlier those individuals for whom specific screening tools and ...
C. Guillén-Ponce, J. Blázquez, I. González, E. de-Madaria, J. Montáns, A. Carrato   +5 more
openaire   +4 more sources

A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling [PDF]

, 2019
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, lethal malignancy that invades adjacent vasculatures and spreads to distant sites before clinical detection.
Alimperti, Styliani, Chen, Christopher S., Eyckmans, Jeroen, Lee, Esak, Lee, Jake June-Koo, Nguyen, Duc-Huy T., Norgard, Robert J., Stanger, Ben Z., Wong, Alec   +8 more
core   +1 more source

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source